Compare PFSI & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFSI | IRTC |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.8B |
| IPO Year | 2013 | 2016 |
| Metric | PFSI | IRTC |
|---|---|---|
| Price | $146.25 | $179.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $148.38 | ★ $207.14 |
| AVG Volume (30 Days) | 307.2K | ★ 409.5K |
| Earning Date | 01-29-2026 | 02-19-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ 191.00 | N/A |
| EPS | ★ 9.30 | N/A |
| Revenue | ★ $2,723,457,000.00 | $702,573,000.00 |
| Revenue This Year | $6.22 | $27.20 |
| Revenue Next Year | $28.90 | $16.91 |
| P/E Ratio | $15.72 | ★ N/A |
| Revenue Growth | 21.25 | ★ 25.45 |
| 52 Week Low | $85.74 | $86.99 |
| 52 Week High | $146.68 | $212.00 |
| Indicator | PFSI | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 78.09 | 52.27 |
| Support Level | $129.37 | $173.46 |
| Resistance Level | $134.91 | $191.40 |
| Average True Range (ATR) | 3.33 | 5.20 |
| MACD | 0.82 | 1.12 |
| Stochastic Oscillator | 94.23 | 51.63 |
PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform and integrated business focused on the production and servicing of U.S. residential mortgage loans. The company operates through two segments: production and servicing. The production segment performs loan origination, acquisition and sale activities. The servicing segment performs loan servicing for newly originated loans.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.